<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6 ADVERSE REACTIONS<BR>               <BR>               <BR>                  <BR>                     <BR>                        Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache (6.1)<BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp. at 1-877-233-2001 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        6.1 Clinical Studies Experience<BR>                     <BR>                     <BR>                        Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice.  <BR>                        The data described below are based on 1387 patients pooled from two double blind, randomized, multicenter, placebo controlled, one-week trials in adult patients with acute, mechanical, lower back pain [see <BR>                                 CLINICAL STUDIES (14)<BR>                               ].  In the study, patients were treated with 350 mg of Carisoprodol Tablets, or placebo three times a day and at bedtime for seven days.  The mean age was about 41 years old with 54% females and 46% males and 74% Caucasian, 16% Black, 9% Asian, and 2% other.<BR>                        There were no deaths and there were no serious adverse reactions in the trial.  In the study, 2.7%, 2%, and 5.4 %, of patients treated with placebo and 350 mg of Carisoprodol Tablets, respectively, discontinued due to adverse events; and 0.5%, 0.5%, and 1.8% of patients treated with placebo and 350 mg of Carisoprodol Tablets, respectively, discontinued due to central nervous system adverse reactions.<BR>                        Table 1 displays adverse reactions reported with frequencies greater than 2% and more frequently than placebo in patients treated with Carisoprodol Tablets in the trial described above.<BR>                        <BR>                           Table 1 – Patients with Adverse Reactions in Controlled Studies<BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center" colspan="6">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">Adverse Reaction</content><BR>                                 </td><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center" colspan="3"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Placebo<br/>(n=560)<br/>n(%)</content><BR>                                       <br/>&#160; <br/>&#160; </paragraph><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">Carisoprodol 350 mg<br/>(n=279)<br/>n(%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center">Drowsiness</td><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">31(6)</td><BR>                                 <td align="center" colspan="2">&#160;</td><BR>                                 <td align="center">47(17)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center">Dizziness</td><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">11(2) </td><BR>                                 <td align="center" colspan="2">&#160;</td><BR>                                 <td align="center">19(7)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center">Headache</td><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">11(2)</td><BR>                                 <td align="center" colspan="2">&#160;</td><BR>                                 <td align="center">9(3)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        6.2 Postmarketing Experience<BR>                     <BR>                     <BR>                        The following events have been reported during postapproval use of Carisoprodol Tablets.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<BR>                        <BR>                           Cardiovascular: Tachycardia, postural hypotension, and facial flushing [see <BR>                                 OVERDOSAGE (10)<BR>                               ].<BR>                        <BR>                           Central Nervous System:  Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures [see <BR>                                 OVERDOSAGE (10)<BR>                               ].<BR>                        <BR>                        <BR>                           Gastrointestinal:  Nausea, vomiting, and epigastric discomfort.<BR>                        <BR>                           Hematologic:  Leukopenia, pancytopenia.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>